Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intracerebral hemorrhage is the least treatable form of stroke. We performed this phase 3 trial to confirm a previous study in which recombinant activated factor VII (rFVIIa) reduced growth of the hematoma and improved survival and functional outcomes. METHODS: We randomly assigned 841 patients with intracerebral hemorrhage to receive placebo (268 patients), 20 microg of rFVIIa per kilogram of body weight (276 patients), or 80 microg of rFVIIa per kilogram (297 patients) within 4 hours after the onset of stroke. The primary end point was poor outcome, defined as severe disability or death according to the modified Rankin scale 90 days after the stroke. RESULTS: Treatment with 80 microg of rFVIIa per kilogram resulted in a significant reduction in growth in volume of the hemorrhage. The mean estimated increase in volume of the intracerebral hemorrhage at 24 hours was 26% in the placebo group, as compared with 18% in the group receiving 20 microg of rFVIIa per kilogram (P=0.09) and 11% in the group receiving 80 microg (P<0.001). The growth in volume of intracerebral hemorrhage was reduced by 2.6 ml (95% confidence interval [CI], -0.3 to 5.5; P=0.08) in the group receiving 20 microg of rFVIIa per kilogram and by 3.8 ml (95% CI, 0.9 to 6.7; P=0.009) in the group receiving 80 microg, as compared with the placebo group. Despite this reduction in bleeding, there was no significant difference among the three groups in the proportion of patients with poor clinical outcome (24% in the placebo group, 26% in the group receiving 20 microg of rFVIIa per kilogram, and 29% in the group receiving 80 microg). The overall frequency of thromboembolic serious adverse events was similar in the three groups; however, arterial events were more frequent in the group receiving 80 microg of rFVIIa than in the placebo group (9% vs. 4%, P=0.04). CONCLUSIONS: Hemostatic therapy with rFVIIa reduced growth of the hematoma but did not improve survival or functional outcome after intracerebral hemorrhage. (ClinicalTrials.gov number, NCT00127283 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1965) · PubMed · Cited by 14,925
ASSESSMENT OF COMA AND IMPAIRED CONSCIOUSNESS
Teasdale, G., & Jennett, B. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91639-0 · Cited by 13,215
Functional evaluation : Barthel index
Mahonery, F. I. (1965) · Medical Entomology and Zoology · Cited by 12,762
Interobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
Measurements of acute cerebral infarction: a clinical examination scale.
Brott, T., Adams, H. P., Olinger, C. P., Marler, J. R., Barsan, W. G., Biller, J., Spilker, J., Holleran, R., Eberle, R., & Hertzberg, V (1989) · Stroke · doi:10.1161/01.str.20.7.864 · Cited by 5,911
WILSON, J. T. L., PETTIGREW, L. E. L., & TEASDALE, G. M. (1998) · Journal of Neurotrauma · doi:10.1089/neu.1998.15.573 · Cited by 2,386
The ICH Score: A Simple, Reliable Grading Scale for Intracerebral Hemorrhage
Hemphill, J. C., Bonovich, D. C., Besmertis, L., Manley, G. T., & Johnston, S. C. (2001) · Stroke · doi:10.1161/01.str.32.4.891 · Cited by 2,196
Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality.
Broderick, J. P., Brott, T. G., Duldner, J. E., Tomsick, T., & Huster, G. (1993) · Stroke · doi:10.1161/01.str.24.7.987 · Cited by 1,746
Self-citationEarly Hemorrhage Growth in Patients With Intracerebral Hemorrhage
Brott, T., Broderick, J., Kothari, R., Barsan, W., Tomsick, T., Sauerbeck, L., Spilker, J., Duldner, J., & Khoury, J. (1997) · Stroke · doi:10.1161/01.str.28.1.1 · Cited by 1,477
Self-citationHematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage
Davis, S. M., Broderick, J., Hennerici, M., Brun, N. C., Diringer, M. N., Mayer, S. A., Begtrup, K., & Steiner, T. (2006) · Neurology · doi:10.1212/01.wnl.0000208408.98482.99 · Cited by 1,168
Self-citation
Research works printed but not linked: 2
- Zimmerman RD, 2006, AJNR Am J Neuroradiol, 27, 666
- Mahoney FI, 1965, Md State Med J, 14, 61
Cited by
Items 401–500 of 1,000
Morotti, A., Li, Q., Nawabi, J., Mazzacane, F., Schlunk, F., Shoamanesh, A., Busto, G., Cavallini, A. M., Palmerini, F., Paciaroni, M., et al. (2025) · Stroke · doi:10.1161/strokeaha.124.049008 · Cited by 33
Self-citationNagao, T., Inden, Y., Shimano, M., Fujita, M., Yanagisawa, S., Kato, H., Ishikawa, S., Miyoshi, A., Okumura, S., Ohguchi, S., et al. (2015) · Internal Medicine · doi:10.2169/internalmedicine.54.3520 · Cited by 30
“Furthermore, we should carefully monitor for the presence of systemic thrombotic emboli because rVIIa and PCC may cause an increased risk of thrombotic complications when the coagulation factors are rapidly replaced during anticoagulation (27, 28).”
BackgroundChoi, B. Y., Kim, O. J., Min, S.-H., Jeong, J. H., Suh, S. W., & Chung, T. N. (2018) · Stem Cells International · doi:10.1155/2018/1658195 · Cited by 33
“approach to improve the prognosis of acute ICH by limiting early hematoma growth via the factor’s acute hemostatic effect, showed potential benefits in an early-phase clinical trial but failed to show a significant effect in a phase III clinical trial [15, 16].”
BackgroundMechanisms of Functional Recovery after Stroke
Ko, S., & Yoon, B. (2013) · Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences · doi:10.1159/000346405 · Cited by 33
Leclerc, J. L., Lampert, A. S., Diller, M. A., & Doré, S. (2015) · European Journal of Neuroscience · doi:10.1111/ejn.12909 · Cited by 30
“Intracerebral hemorrhage (ICH) is a devastating stroke subtype with no effective treatments (Sahni & Weinberger, 2007; Mayer et al., 2008; Rincon & Mayer, 2008; Crandall et al., 2011).”
BackgroundSCORE-IT: the Spot Sign score in restricting ICH growth─an Atach-II ancillary study.
Goldstein, J., Brouwers, H., del Romero, J. O., McNamara, K. A., Schwab, K. M., Greenberg, S., & Rosand, J. M. (2012) · Europe PMC (PubMed Central) · Cited by 30
Pontes‐Neto, O. M., Fernandes, R. M. F., Sander, H. H., da Silva, L. A. T., Mariano, D. C., Nobre, F. D., Simão, G. N., de Araújo, D. B., dos Santos, A. C., & Leite, J. P. (2009) · Cerebrovascular Diseases · doi:10.1159/000255972 · Cited by 30
“These findings give biological plausibility for the association between OSA and perihematoma edema, but the role of matrix metalloproteinase-9 on this association needs to be addressed by additional studies in the future.There are some limitations to our study, mainly related to a relatively small sample size. As expe…”
BackgroundTreatment Targets in Intracerebral Hemorrhage
Sangha, N. S., & Gonzales, N. R. (2011) · Neurotherapeutics · doi:10.1007/s13311-011-0055-z · Cited by 33
“The percent of arterial thromboembolic events was 10% in the 80 μg/kg group and 5% in the placebo group, without any difference in venous thromboembolism [56].”
Leal-Noval, S. R., Múñoz, M., Asuero, M., Contreras, E., García‐Erce, J. A., Llau, J. V., Moral, V., Páramo, J. A., Quintana, M., Basora, M., et al. (2013) · Medicina Intensiva · doi:10.1016/j.medin.2012.12.013 · Cited by 37
The role of thromboelastometry and recombinant factor VIIa in trauma
Bartal, C., & Yitzhak, A. (2009) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e328325a6be · Cited by 30
Kim, H.-T., Lee, J.-M., Koh, E., & Choi, H. (2015) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2015.58.4.309 · Cited by 34
Li, Q., Li, L.-J., Wang, X., Sun, Y., & Wu, J. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00682 · Cited by 30
Dutton, R. P., Hauser, C. J., Boffard, K. D., Dimsitts, J., Bernard, G. R., Holcomb, J. B., Leppäniemi, A. K., Tortella, B., & Bouillon, B. (2009) · Clinical Trials · doi:10.1177/1740774509344102 · Cited by 33
Intracerebral Hemorrhage — Improving Outcome by Reducing Volume?
Tuhrim, S. (2008) · New England Journal of Medicine · doi:10.1056/nejme0801856 · Cited by 30
Ekezue, B. F., Sridhar, G., Ovanesov, M. V., Forshee, R. A., Izurieta, H. S., Selvam, N., Parunov, L. A., Jain, N., Mintz, P. D., Epstein, J. S., et al. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13155 · Cited by 29
Yang, W., Zhang, S., Shen, Y., Xiao, W., Zhao, L., Xie, X., Deng, L., Li, X., Lv, X., Lv, F., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.018248 · Cited by 30
Zeng, X., He, G., Yang, X., Xu, G., Tang, Y., Li, H., Yu, B., Wang, Z., Xu, W., & Song, K. (2022) · Bioengineered · doi:10.1080/21655979.2021.2024323 · Cited by 31
“The expression level of VEGF is elevated by the activation of the AMPK pathway [25].”
BackgroundBrown, C. V. R., Foulkrod, K. H., Lopez, D., Stokes, J., Villareal, J., Foarde, K., Curry, E. A., & Coopwood, B. (2010) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e3181bbfb6b · Cited by 29
Wacker, D. A., & Winters, M. E. (2014) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2014.07.003 · Cited by 29
Management of acute intracranial and intraventricular hemorrhage
Nyquist, P. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181d16a04 · Cited by 31
“The drug fVIIa currently is not approved for use in ICH by the Food and Drug Administration (51, 66, 67).”
BackgroundCorrection of coagulopathy in warfarin associated cerebral hemorrhage
Aiyagari, V., & Testai, F. D. (2009) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e3283269e4d · Cited by 29
Update on Blood Conservation for Cardiac Surgery
Nalla, B. P., Freedman, J. J., Hare, G. M. T., & Mazer, C. D. (2011) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2011.07.024 · Cited by 37
Moreton Lecture: Imaging in the Age of Precision Medicine
Thrall, J. H. (2015) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2015.06.003 · Cited by 28
Hematoma expansion in intracerebral hemorrhage – the right target?
Haupenthal, D., Schwab, S., & Kuramatsu, J. B. (2023) · Neurological Research and Practice · doi:10.1186/s42466-023-00256-6 · Cited by 28
Natural history of complications after intracerebral haemorrhage
Ali, M., Lyden, P. D., Sacco, R. L., Shuaib, A. M., Lees, K. R., & for the VISTA investigators (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02559.x · Cited by 28
Advanced CT Imaging in the Evaluation of Hemorrhagic Stroke
Almandoz, J. E. D., & Romero, J. M. (2011) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2011.01.001 · Cited by 28
Tissue Factor in Brain Is Not Saturated With Factor VIIa
Hoffman, M., & Monroe, D. M. (2009) · Stroke · doi:10.1161/strokeaha.109.555433 · Cited by 28
Salihu, A. T., Muthuraju, S., Idris, Z., Ghani, A. R. I., & Abdullah, J. M. (2015) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0046 · Cited by 29
Rodríguez, J. A., Sobrino, T., López‐Arias, E., Ugarte, A., Sánchez-Arias, J. A., Prado, A. V., de Miguel, I., Oyarzábal, J., Páramo, J. A., Campos, F., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006042 · Cited by 28
Using Prothrombin Complex Concentrates to Rapidly Reverse Oral Anticoagulant Effects
Dager, W. E. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q288 · Cited by 28
Predictors of severe intracerebral hemorrhage expansion
Morotti, A., Li, Q., Nawabi, J., Busto, G., Mazzacane, F., Cavallini, A. M., Shoamanesh, A., Morassi, M., Schlunk, F., Piccolo, L., et al. (2024) · European Stroke Journal · doi:10.1177/23969873241247436 · Cited by 30
“18,19 Finally, multiple HE prediction tools and nomograms have been developed and it might be of interest to test their diagnostic performance for sHE.”
Emergency Neurological Life Support: Pharmacotherapy
Brophy, G. M., Human, T., & Shutter, L. (2015) · Neurocritical Care · doi:10.1007/s12028-015-0158-1 · Cited by 28
“Factor VIIa Recombinant activated factor VII (rFVIIa) was shown to decrease hematoma growth in noncoagulopathic ICH patients; however, no improvement in mortality was demonstrated in a large randomized trial so it is not recommended in this patient population [39].”
BackgroundClimatic and Seasonal Circumstances of Hypertensive Intracerebral Hemorrhage in a Worldwide Cohort
Herweh, C., Nordlohne, S., Sykora, M., Uhlmann, L., Bendszus, M., & Steiner, T. (2017) · Stroke · doi:10.1161/strokeaha.117.018779 · Cited by 27
Self-citationComputed Tomography Imaging Predictors of Intracerebral Hemorrhage Expansion
Lv, X., Deng, L., Yang, W., Xiao, W., & Li, Q. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-021-01108-z · Cited by 31
Using Noncontrast Computed Tomography to Improve Prediction of Intracerebral Hemorrhage Expansion
Morotti, A., Boulouis, G., Nawabi, J., Li, Q., Charidimou, A., Pasi, M., Schlunk, F., Shoamanesh, A., Katsanos, A. H., Mazzacane, F., et al. (2023) · Stroke · doi:10.1161/strokeaha.122.041302 · Cited by 27
Novel Approaches to the Treatment of Intracerebral Haemorrhage
Staykov, D., Huttner, H. B., Köhrmann, M., Bardutzky, J., & Schellinger, P. D. (2010) · International Journal of Stroke · doi:10.1111/j.1747-4949.2010.00487.x · Cited by 31
Naidech, A. M., Beaumont, J. L., Berman, M. D., Liotta, E. M., Maas, M. B., Prabhakaran, S., Kording, K. P., Holl, J. L., & Cella, D. F. (2014) · Neurocritical Care · doi:10.1007/s12028-014-0098-1 · Cited by 27
Rizos, T., Dörner, N., Jenetzky, E., Sykora, M., Mundiyanapurath, S., Horstmann, S., Veltkamp, R. C., Rohde, S., Bendszus, M., & Steiner, T. (2013) · Cerebrovascular Diseases · doi:10.1159/000348851 · Cited by 27
Self-citationSurgery for Intracerebral Hemorrhage
Flaherty, M. L., & Beck, J. (2013) · Stroke · doi:10.1161/strokeaha.113.002533 · Cited by 27
Intracerebral Hemorrhage: A Multimodality Approach to Improving Outcome
Pandey, A. S., & Xi, G. (2014) · Translational Stroke Research · doi:10.1007/s12975-014-0344-z · Cited by 29
“Results of the FAST trial revealed a similar ability to reduce hematoma expansion as was observed in the phase II trial; however, there were no significant differences in mortality among the control (24 %), low-dose (26 %), and high-dose (29 %) factor VIIa patients [13].”
ResultYuan, Q., Wu, X., Du, Z., Sun, Y., Yu, J., Li, Z., Wu, X., Mao, Y. Q., Zhou, L., & Hu, J. (2014) · Journal of Critical Care · doi:10.1016/j.jcrc.2014.07.009 · Cited by 26
“Moreover, Mayer et al [25] found that arterial events were more frequent in patients with intracerebral hemorrhage receiving 80 μg/kg rFVIIa than in placebo patients, but there were no significant differences between the 20 μg/kg and placebo groups.”
BackgroundTargeting Secondary Hematoma Expansion in Spontaneous Intracerebral Hemorrhage – State of the Art
Guan, J., & Hawryluk, G. W. J. (2016) · Frontiers in Neurology · doi:10.3389/fneur.2016.00187 · Cited by 26
“001 for the high-dose group versus 26% increase for placebo) (77).”
BackgroundHematoma enlargement characteristics in deep versus lobar intracerebral hemorrhage
Sembill, J. A., Kuramatsu, J. B., Gerner, S. T., Sprügel, M. I., Roeder, S. S., Madžar, D., Hagen, M., Hoelter, P., Lücking, H., Dörfler, A., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51001 · Cited by 31
“However, the FAST and the TICH-2 studies demonstrated reduced rates of HE achieved by tested hemostatic interventions, yet without translating to primary disability outcomes.(9,10) The present study results suggest that association of HE with functional outcome is more pronounced in deep compared to lobar ICH, likely…”
ResultArba, F., Rinaldi, C., Boulouis, G., Fainardi, E., Charidimou, A., & Morotti, A. (2021) · International Journal of Stroke · doi:10.1177/17474930211061639 · Cited by 29
Haider, S. P., Qureshi, A. I., Jain, A. P., Tharmaseelan, H., Berson, E. R., Zeevi, T., Werring, D. J., Gross, M., Mak, A., Malhotra, A., et al. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1225342 · Cited by 27
“, 2016), nor administration of hemostatic drugs such as recombinant factor VII (Mayer et al., 2008) or tranexamic acid (Sprigg et al.”
BackgroundTanaka, Y., Marumo, T., Shibuta, H., Omura, T., & Yoshida, S. (2008) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2008.10.012 · Cited by 26
Alam, H. B., & Velmahos, G. C. (2011) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2011.04.002 · Cited by 31
Attitudes of Patients and Relatives Toward Disability and Treatment in Malignant MCA Infarction
for the IGNITE Study Group (Initiative of German NeuroIntensive Trial Engagement), Neugebauer, H., Schnabl, M., Lulé, D. E., Heuschmann, P. U., & Jüttler, E. (2016) · Neurocritical Care · doi:10.1007/s12028-016-0362-7 · Cited by 28
Neuroprotective strategies following intraparenchymal hemorrhage
Babadjouni, R., Radwanski, R. E., Walcott, B. P., Patel, A. B., Durazo, R., Hodis, D. M., Emanuel, B. A., & Mack, W. J. (2017) · Journal of NeuroInterventional Surgery · doi:10.1136/neurintsurg-2017-013197 · Cited by 29
Hematoma Expansion Shift Analysis to Assess Acute Intracerebral Hemorrhage Treatments
Yogendrakumar, V., Ramsay, T., Menon, B. K., Qureshi, A. I., Saver, J. L., & Dowlatshahi, D. D. (2021) · Neurology · doi:10.1212/wnl.0000000000012393 · Cited by 28
He, K.-L., Yu, X., Xia, L., Xie, Y., Qi, E., Wan, L., Hua, X., & Jing, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1526786 · Cited by 33
Rodrigues, M. A., Samarasekera, N., Lerpiniere, C., Perry, L. A., Moullaali, T. J., Loan, J. J., Wardlaw, J. M., Salman, R. A., & Collaborators, F. T. L. A. O. T. T. O. C. H. (2020) · Annals of Neurology · doi:10.1002/ana.25949 · Cited by 26
“1 60 (34) 94 (42) 2 29 (16) 62 (28) 3 7 (4) 14 (6)”
Mayer, S. A., Frontera, J. A., Jankowitz, B. T., Kellner, C. P., Kuppermann, N., Naik, B. I., Nishijima, D. K., Steiner, T., Goldstein, J. N., CNS Bleeding/Neurosurgery Subgroup of the NHLBI Hemostasis Trials Outcomes Working Group, et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.23629 · Cited by 25
Self-citationChong, C., Lew, T. W. K., Kuperan, P., Tan, J., Tan, H., & Kwek, T. K. (2010) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1003800310 · Cited by 25
Impact of an innovative blood factor stewardship program on drug expense and patient care
Amerine, L. B., Chen, S., Daniels, R., Key, N. S., Eckel, S. F., & Savage, S. W. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140722 · Cited by 25
Intracerebral Hemorrhage: A Review of Coagulation Function
Emiru, T., Bershad, E. M., Zantek, N. D., Datta, Y. H., Rao, G. H. R., Hartley, E. W., & Divani, A. A. (2012) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612454938 · Cited by 26
“This study did not find improved survival or functional outcome in the rFVIIa treatment groups.(50) In addition, a review of 17 randomized controlled trials in which rFVIIa was used to reduce bleeding in patients with a variety of clinical conditions including ICH concluded that this therapy reduced ICH expansion as w…”
ResultOkishige, K., Nakamura, T., Aoyagi, H., Kawaguchi, N., Yamashita, M., Kurabayashi, M., Suzuki, H., Asano, M., Shimura, T., Yamauchi, Y., et al. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2016.04.009 · Cited by 27
Medical management of acute intracerebral hemorrhage
Anderson, C. S. (2009) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e328325d12c · Cited by 28
Patel, V. D., García, R. M., Swor, D. E., Liotta, E. M., Maas, M. B., & Naidech, A. M. (2020) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2020.104920 · Cited by 24
Qureshi, A. I., Lobanova, I., Huang, W., Ishfaq, M. F., Broderick, J. P., Cassarly, C. N., Martin, R. H., Macdonald, R. L., & Suárez, J. I. (2021) · Neurocritical Care · doi:10.1007/s12028-021-01372-4 · Cited by 25
“Another prominent discrepancy was seen in phase II b trial [80] and phase III trial [81] evaluating the use of recombinant factor VII in patents with intracerebral hemorrhage.”
BackgroundSelf-citationWu, G., Liu, Z., Mu, C., Song, D. F., Wang, J., Meng, X., Li, Z., Qing, H., Dong, Y., Xie, H., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c11329 · Cited by 25
Rational Use of Recombinant Factor VIIa in Clinical Practice
Dutta, T. K., & Verma, S. (2013) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-013-0240-9 · Cited by 24
New Avenues for Treatment of Intracranial Hemorrhage
Sonni, S., Lioutas, V., & Selim, M. H. (2013) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-013-0277-y · Cited by 26
Ongoing Clinical Trials in Intracerebral Hemorrhage
Gonzales, N. R. (2013) · Stroke · doi:10.1161/strokeaha.111.000563 · Cited by 24
The Challenge of Designing a Treatment Trial for Warfarin-Associated Intracerebral Hemorrhage
Flaherty, M. L., Adeoye, O. M., Sekar, P., Haverbusch, M. A., Moomaw, C. J., Tao, H., Broderick, J. P., & Woo, D. (2009) · Stroke · doi:10.1161/strokeaha.108.538462 · Cited by 24
Self-citationMajor publications in the critical care pharmacotherapy literature in 2015
Wong, A., Erdman, M. J., Hammond, D. A., Holt, T., Holzhausen, J. M., Horng, M., Huang, L. L., Jarvis, J., Kram, B., Kram, S. J., et al. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160144 · Cited by 24
“as well as PCCs, and may increase the risk for thrombosis.(23)”
BackgroundSykora, M., Herweh, C., & Steiner, T. (2017) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2017.02.003 · Cited by 24
Self-citationOvesen, C., Jakobsen, J. C., Gluud, C. N., Steiner, T., Law, Z. K., Flaherty, K., Dineen, R. A., Christensen, L. M., Overgaard, K., Rasmussen, R. S., et al. (2021) · Stroke · doi:10.1161/strokeaha.120.032426 · Cited by 24
Self-citationIntensive Care Management of Acute Stroke: General Management
Diedler, J., Sykora, M., Jüttler, E., Steiner, T., & Hacke, W. (2009) · International Journal of Stroke · doi:10.1111/j.1747-4949.2009.00338.x · Cited by 24
Self-citationRisks and benefits of CT angiography in spontaneous intracerebral hemorrhage
Hotta, K., Sorimachi, T., Osada, T., Baba, T., Inoue, G., Atsumi, H., Ishizaka, H., Matsuda, M., Hayashi, N., & Matsumae, M. (2014) · Acta Neurochirurgica · doi:10.1007/s00701-014-2019-7 · Cited by 24
“Two phase II trials of rFVIIa in ICH patients using spot sign selection are underway in Canada and the United states [10, 11], though improvement in survival and functional outcomes by use of rFVIIa were not found in a large phase III randomized control trial without spot sign selection [17, 18].”
Methodd’Esterre, C. D., Fainardi, E., Aviv, R. I., & Lee, T. Y. (2012) · Translational Stroke Research · doi:10.1007/s12975-012-0178-5 · Cited by 26
“Reduction in blood pressure along with the administration of recombinant factor VIIa may relieve hematoma expansion; however, improvement in clinical outcome has not been shown, except in a small subset of patients [129, 130].”
BackgroundDeveloping predictive models of excellent and devastating outcome after stroke
Reid, J. M., Dai, D., Christian, C. A., Reidy, Y., Counsell, C. E., Gubitz, G. J., & Phillips, S. J. (2012) · Age and Ageing · doi:10.1093/ageing/afs034 · Cited by 24
“However, studies of hemicraniectomy for malignant stroke and a therapeutic trial in haemorrhagic stroke have used outcomes of survival with mild dependence (mRS of 0–3) and a devastating outcome (mRS of 5–6), respectively [2, 3].”
BackgroundHerweh, C., Prager, E. P., Sykora, M., & Bendszus, M. (2013) · Stroke · doi:10.1161/strokeaha.111.670901 · Cited by 24
Intracerebral Hemorrhage: Advances, Knowledge Gaps, and Future Directions
Liu, T., Jiang, W., Zhang, M., Xiong, S., Chen, L., Chen, X., & Jiang, R. (2025) · MedComm · doi:10.1002/mco2.70436 · Cited by 27
Dynamic nature of the CT angiographic “spot sign”
Chakraborty, S., Blacquière, D., Lum, C., & Stotts, G. (2010) · British Journal of Radiology · doi:10.1259/bjr/74416385 · Cited by 23
Impact of Recent Studies for the Treatment of Intracerebral Hemorrhage
Sembill, J. A., Huttner, H. B., & Kuramatsu, J. B. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0872-0 · Cited by 24
Clinical Strategies Against Early Hematoma Expansion Following Intracerebral Hemorrhage
Tanaka, K., & Toyoda, Ḱ. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.677744 · Cited by 25
Non-contrast CT markers of intracerebral hemorrhage expansion: The influence of onset-to-CT time
Morotti, A., Li, Q., Mazzoleni, V., Nawabi, J., Schlunk, F., Mazzacane, F., Busto, G., Scola, E., Brancaleoni, L., Giacomozzi, S., et al. (2022) · International Journal of Stroke · doi:10.1177/17474930221142742 · Cited by 25
Huang, Y., Huang, H., Li, Z., & Yin, X.-S. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1176390 · Cited by 29
“5 h, as demonstrated in the Factor VII for Acute Hemorrhagic Stroke Trial (FAST) experiment (97, 98).”
MethodUse of rFVIIa for critical bleeding in cardiac surgery: dose variation and patient outcomes
Willis, C., Bird, R. J., Mullany, D. V., Cameron, P. A., & Phillips, L. E. (2009) · Vox Sanguinis · doi:10.1111/j.1423-0410.2009.01276.x · Cited by 23
Management of Excessive Anticoagulant Effect Due to Vitamin K Antagonists
Dentali, F., & Crowther, M. A. (2008) · Hematology · doi:10.1182/asheducation-2008.1.266 · Cited by 23
Timing of Occurrence Is the Most Important Characteristic of Spot Sign
Wang, B., Yan, S., Xu, M., Zhang, S., Liu, K., Hu, H., Selim, M. H., & Lou, M. (2016) · Stroke · doi:10.1161/strokeaha.116.012697 · Cited by 24
Diretrizes para o manejo de pacientes com hemorragia intraparenquimatosa cerebral espontânea
Pontes‐Neto, O. M., Filho, J. O., Valiente, R. A., Friedrich, M., Pedreira, B. B., Rodrigues, B., Liberato, B. B., & de Freitas, G. R. (2009) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2009000500034 · Cited by 82
The Pattern and Pace of Hyperacute Hemorrhage Expansion
Edlow, B. L., Bove, R. M., Viswanathan, A., Greenberg, S. M., & Silverman, S. B. (2012) · Neurocritical Care · doi:10.1007/s12028-012-9738-5 · Cited by 25
“New methods for reducing hematoma expansion are being actively sought, since previously reported approaches such as hemostatic therapy [17] and blood pressure reduction [18, 19] have yet to demonstrate clinical benefit.”
D’Amore, C., Paciaroni, M., Silvestrelli, G., Agnelli, G., Santucci, P., Lanari, A., Alberti, A., Venti, M. P., Acciarresi, M., & Caso, V. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2012.12.007 · Cited by 24
Intracranial haemorrhage: therapeutic interventions and anaesthetic management
Mack, P. F. (2014) · British Journal of Anaesthesia · doi:10.1093/bja/aeu397 · Cited by 26
Babi, M.-A., & James, M. L. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00004 · Cited by 22
“While initial preliminary data suggested that Factor VIIa may be safe (40, 41), results from a phase-3 randomized controlled trial showed that although recombinant factor VIIa use after ICH resulted in significant reduction in hematoma volume but no reduction in severe disability or death compared to placebo at 3 mont…”
ResultPredictors of hemorrhage volume and disability after perimesencephalic subarachnoid hemorrhage
Naidech, A. M., Rosenberg, N. F., Maas, M. B., Bendok, B. R., Batjer, H. H., & Nemeth, A. J. (2012) · Neurology · doi:10.1212/wnl.0b013e318249f6dc · Cited by 22
Frequency of Hematoma Expansion After Spontaneous Intracerebral Hemorrhage in Children
Beslow, L. A., Ichord, R., Gindville, M. C., Kleinman, J. T., Bastian, R. A., Smith, S. E., Licht, D. J., Hillis, A. E., & Jordan, L. C. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4672 · Cited by 22
Chang, J. J., Khorchid, Y. M., Kerro, A., Burgess, L. G., Goyal, N., Alexandrov, A. W., Alexandrov, A. V., & Tsivgoulis, G. K. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.08.3252 · Cited by 22
Min, S.-H., Kim, O. J., Bae, J., & Chung, T. N. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113679 · Cited by 22
Chang, J. C. (2020) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029620913634 · Cited by 22
Extracellular matrix metalloproteinase inducer in brain ischemia and intracerebral hemorrhage
Liu, Y., Mu, Y., Li, Z., Yong, V. W., & Xue, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.986469 · Cited by 22
“To treat hemorrhagic strokes, hemostasis and surgical approaches are the main procedure although they do not significantly improve cl inical outcomes (14, 15).”
BackgroundLaw, Z. K., Meretoja, A., Engelter, S. T., Christensen, H., Lupan-Mureșan, E.-M., Glad, S. B., Liu, L., Bath, P. M., & Sprigg, N. (2016) · European Stroke Journal · doi:10.1177/2396987316676610 · Cited by 22
“The TICH-2 trial is recruiting ICH patients presenting within 8 h of onset regardless of whether they had CT angiography to detect positive spot sign, a predictor of HE.”
BackgroundInfluentialSpot Sign in Intracerebral Hemorrhage: Critical Reappraisal and Future Clinical Implications
Pensato, U., Dowlatshahi, D. D., Rodríguez‐Luna, D., Ospel, J. M., Morotti, A., Tanaka, K., Yogendrakumar, V., Romero, J. M., Brouwers, H. B., Davis, S. M., et al. (2025) · Stroke · doi:10.1161/strokeaha.125.050637 · Cited by 21
Self-citationApplication of nanomaterials in the treatment of intracerebral hemorrhage
Zhang, X., Khan, S., Wei, R., Zhang, Y., Liu, Y., Yong, V. W., & Xue, M. (2023) · Journal of Tissue Engineering · doi:10.1177/20417314231157004 · Cited by 21
“1 Neuroinflammation and oxidative stress are involved in secondary brain injury after ICH, 2–4 and the extensive literature on these pathogenic mechanisms uncover new insights to counter the pathologic sequelae of ICH.”
BackgroundInfluentialNew Oral Anticoagulants and Their Reversal Agents
Morotti, A., & Goldstein, J. N. (2016) · Current Treatment Options in Neurology · doi:10.1007/s11940-016-0430-5 · Cited by 24
Intracerebral haemorrhage: no good treatment but treatment helps
Rabinstein, A. A. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30002-8 · Cited by 21
Yassi, N., Zhao, H. H., Churilov, L. P., Campbell, B. C. V., Wu, T. Y., Ma, H., Cheung, A. K., Kleinig, T. J., Brown, H., Choi, P. M. C., et al. (2021) · Stroke and Vascular Neurology · doi:10.1136/svn-2021-001070 · Cited by 21
Self-citationAn Update on Surgical and Medical Management Strategies for Intracerebral Hemorrhage
Kreitzer, N. P., & Adeoye, O. M. (2014) · Seminars in Neurology · doi:10.1055/s-0033-1364210 · Cited by 21
Metadata
- Authors
- Mayer, S. A., Brun, N. C., Begtrup, K., Broderick, J., Davis, S., Diringer, M. N., Skolnick, B. E., & Steiner, T.
- Affiliations
- Columbia University Irving Medical Center (US)
- Novo Nordisk (Denmark) (DK)
- University of Cincinnati Medical Center (US)
- The Royal Melbourne Hospital (AU)
- Washington University in St. Louis (US)
- Heidelberg University (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-15
- Volume
- 358
- Issue
- 20
- Pages
- 2127-2137
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2142640478
- Cited by
- 1,255
- References
- 29
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 44 · 2023: 36 · 2022: 38 · 2021: 75 · 2020: 71 · 2019: 57 · 2018: 59 · 2017: 75 · 2016: 60 · 2015: 68 · 2014: 77 · 2013: 90 · 2012: 105
- FWCI
- 70.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Health Sciences › Medicine › Clinical Neurology › Intracranial Aneurysms: Treatment and Complications
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- recombinant factor VIIa, intracerebral hemorrhage, hematoma expansion, hemorrhagic stroke, thromboembolic adverse events, functional outcome, modified Rankin Scale, hemostatic therapy, dose comparison, arterial events, bleeding complications, arterial thrombosis, venous thromboembolism
- MeSH terms
- Adult, Aged, Aged, 80 and over, Cerebral Hemorrhage, Double-Blind Method, Female, Hematoma, Humans, Male, Middle Aged, Recombinant Proteins, Tomography, X-Ray Computed, Glasgow Coma Scale, Factor VIIa, Treatment Failure, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.